The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
The Impact of Molecular Weight and PEG Chain Length on the Systemic Pharmacokinetics of PEGylated Poly l-Lysine Dendrimers
Abstract
The impact of PEGylation on the pharmacokinetics and biodistribution of (3)H-labeled poly l-lysine dendrimers has been investigated after intravenous administration to rats. The volumes of distribution, clearance and consequently the plasma half-lives of the PEGylated dendrimers were markedly dependent on the total molecular weight of the PEGylated dendrimer, but were not specifically affected by the PEG chain length alone. In general, the larger dendrimer constructs (i.e. >30 kDa) had reduced volumes of distribution, were poorly renally cleared and exhibited extended elimination half-lives ( t 1/2 1-3 days) when compared to the smaller dendrimers (i.e. <20 kDa) which were rapidly cleared from the plasma principally into the urine ( t 1/2 1-10 h). At later time points the larger dendrimers concentrated in the organs of the reticuloendothelial system (liver and spleen); however, the absolute extent of accumulation was low. Size exclusion chromatography of plasma and urine samples revealed that the PEGylated dendrimers were considerably more resistant to biodegradation in vivo than the underivatized poly l-lysine dendrimer cores. The results suggest that the size of PEGylated poly l-lysine dendrimer complexes can be manipulated to optimally dictate their pharmacokinetics, biodegradation and bioresorption behavior.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
Cited by
Nanomaterials: Applications in Cancer Imaging and Therapy
Barreto, J. A., O’Malley, W., Kubeil, M., Graham, B., Stephan, H., & Spiccia, L. (2011) · Advanced Materials · doi:10.1002/adma.201100140 · Cited by 907
Effects of nanomaterial physicochemical properties on in vivo toxicity
Aillon, K. L., Xie, Y., El-Gendy, N., Berkland, C. J., & Forrest, M. L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.010 · Cited by 811
Cheng, Y., Zhao, L., Li, Y., & Xu, T. (2011) · Chemical Society Reviews · doi:10.1039/c0cs00097c · Cited by 515
Effect of physicochemical and surface properties on in vivo fate of drug nanocarriers
Zhao, Z., Ukidve, A., Krishnan, V., & Mitragotri, S. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2019.01.002 · Cited by 444
van Dongen, S. F. M., de Hoog, H.-P. M., Peters, R. J. R. W., Nallani, M., Nolte, R. J. M., & van Hest, J. C. M. (2009) · Chemical Reviews · doi:10.1021/cr900072y · Cited by 386
Designing Smart Polymer Conjugates for Controlled Release of Payloads
Seidi, F., Jenjob, R., & Crespy, D. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00006 · Cited by 316
Mulet, X., Boyd, B. J., & Drummond, C. J. (2013) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2012.10.014 · Cited by 315
Self-citationShe, W., Luo, K., Zhang, C., Wang, G., Geng, Y., Li, L., He, B., & Gu, Z. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2012.11.007 · Cited by 276
Cyclometalated iridium(III) complexes for life science
Caporale, C., & Massi, M. (2018) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2018.02.006 · Cited by 258
Kaminskas, L. M., Kelly, B. D., McLeod, V. M., Sberna, G., Owen, D. J., Boyd, B. J., & Porter, C. J. H. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.005 · Cited by 137
Self-citationKaminskas, L. M., Kelly, B. D., McLeod, V. M., Sberna, G., Boyd, B. J., Owen, D. J., & Porter, C. J. H. (2011) · Molecular Pharmaceutics · doi:10.1021/mp1001872 · Cited by 64
Metadata
- Authors
- Kaminskas, L. M., Boyd, B. J., Karellas, P., Krippner, G. Y., Lessene, R., Kelly, B., & Porter, C. J. H.
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2008-04-05
- Volume
- 5
- Issue
- 3
- Pages
- 449-463
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- OpenAlex
- W1982518352
- Cited by
- 178
- References
- 1
- FWCI
- 14.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.